Lixte Biotechnology
East Setauket
About Lixte Biotechnology
Lixte Biotechnology is a clinical-stage public pharmaceutical company that focuses on discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $22.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Dec 2025)
- Ticker: otcqb:LIXT
- Website: lixte.com
- Phone: (631) 830-7092
Industries & Categories
Biotechnology, Health Care, Oncology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/lixte-biotechnology-62929 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.